NEUWAY Pharma GmbH
NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical development of innovative therapeutics for treatment of severe orphan brain diseases based on its proprietary CNS Drug Delivery Platform. The company also intends to partner its drug delivery technology for application to proprietary compounds of pharmaceutical companies to exploit its therapeutic use in the field of CNS indications. Beside that NEUWAY initiated the development of a vaccine to treat a rare but frequently fatal neurological disease called progressive multifocal leucoencephalopathy (PML).
NEUWAY had been founded in April 2014 as the first spin-off from Life Science Inkubator GmbH, Bonn, Germany, where it had been incubated and supported with approx. € 2.3 million in research funding by the Federal Ministry of Education and Research. The company closed a series A financing round in May 2014 with a volume of € 2.7 million provided by a syndicate led by Wellington Partners. Funding was extended to a total of € 5.85 million in Oct. 2015 with an additional contribution of € 2.0 million by the lead investor. Life Science Inkubator, Kreditanstalt für Wiederaufbau (KfW) and several private shareholders also participated in the financing rounds. In addition, NEUWAY Pharma GmbH received a € 2.93 million BMBF (Federal Ministry of Education and Research) grant in August 2015 for advancing its CNS Drug Delivery Platform.
Neuway had been founded in April 2014